ADHD Medications: Amphetamines vs. Methylphenidates - Efficacy, Risks, and Best Practices

Поделиться
HTML-код
  • Опубликовано: 13 сен 2024
  • A thorough comparison of amphetamines and methylphenidate, focusing on efficacy, tolerability, psychiatric risks, and adult ADHD diagnosis.
    Content written by: Chris Aiken, MD
    💡Carlat Webinars: www.thecarlatr...
    📖Subscribe to The Carlat Journal: www.thecarlatr...
    ➡️Earn CME Credits for this video: thecarlatrepor...
    ================
    Follow Carlat:
    🔴SUBSCRIBE ► / @thecarlatreport
    ➡️Twitter: / CarlatPsych
    ================
    A 30-minute webinar for CME credit by Chris Aiken, MD, Editor-in-Chief of The Carlat Psychiatry Report. Dr. Aiken is a practicing psychiatrist in Winston-Salem, NC; director of the Mood Treatment Center in North Carolina; and Assistant Professor NYU Langone Department of Psychiatry.
    Highlights
    🧠 Mechanism: Amphetamines release dopamine, while methylphenidate blocks its reuptake.
    📊 Efficacy: Meta-analyses show amphetamines generally have a greater effect size than methylphenidate.
    💊 Tolerability: Methylphenidate is better tolerated with fewer side effects compared to amphetamines.
    ⚠️ Psychiatric Risks: Amphetamines may pose higher risks for psychosis and mania, especially in vulnerable populations.
    🔍 Diagnosis: Adult ADHD diagnosis is complex; symptoms can overlap with other psychiatric disorders.
    🏥 Treatment: Methylphenidate is often preferred as first-line treatment in adults due to its safety profile.
    📈 Trends: Historical data shows a shift in stimulant prescriptions from amphetamines to methylphenidate in adults.
    Key Insights
    ⚙️ Mechanism of Action: Understanding the differing mechanisms of amphetamines and methylphenidate is crucial for effective treatment choices. Amphetamines provide a more immediate increase in dopamine, which may lead to stronger effects but also a higher potential for side effects. 🧠
    📈 Efficacy Differences: While amphetamines generally demonstrate a larger effect size, individual responses vary. Some patients may find methylphenidate more effective, emphasizing the need for personalized treatment approaches. 📊
    😌 Tolerability and Side Effects: Methylphenidate tends to be better tolerated than amphetamines, suggesting it may be a safer option for patients, particularly those with complex comorbidities. 💊
    ⚠️ Psychiatric Risks: The risk of developing psychosis or mania is a significant concern, particularly with amphetamines. This highlights the importance of closely monitoring patients with a history of psychiatric disorders. ⚠️
    🧩 Complex Diagnosis: The diagnosis of adult ADHD can be challenging due to overlapping symptoms with other conditions like PTSD or bipolar disorder, necessitating thorough assessments. 🔍
    🏥 First-Line Treatment: Methylphenidate is often recommended as the first-line treatment in adults due to its favorable side effect profile, reflecting a shift in prescribing practices. 🏥
    📜 Historical Context: Understanding the historical prescribing trends of stimulants can inform current practices and help avoid potential biases towards amphetamines. 📈

Комментарии • 14

  • @Khpr666
    @Khpr666 3 месяца назад +3

    This is what a doctor should do. People should be selected and trained to practice like Dr. Aiken.

  • @LeoMoncler
    @LeoMoncler Год назад +4

    This is exactly what I was looking for. I wanted to see which stimulant helps with GAD and social anxiety. Learned a lot more than I expected. Thank you for your detailed analysis

  • @artistrobinhuber
    @artistrobinhuber Год назад +2

    This was fantastic. Exactly the kind of information I was looking for but is so hard to find. Thank you!

  • @jamiltube7663
    @jamiltube7663 Год назад +1

    This is a very detailed report I use dexmethylphenidate and while it may not be as effective or euphoric it still does make a big difference in everyday life and I recommend it to people who want a safe stimulant that’s not gonna lead to any erratic behaviors.

  • @TalkingwithHas
    @TalkingwithHas Год назад +1

    Very well done report. Best regards

  • @gail9982
    @gail9982 Месяц назад

    Thank you! I’ve been looking for information comparing methylphenidate vs amphetamine for a couple of years. I am a late middle aged adult female who has definitely had ADHD (yes little girls can be hyper active!) since early childhood. I am meeting with my psychiatrist this afternoon and I definitely want to explore switching to a Ritalin type product.

  • @dalmatiantoadflax5798
    @dalmatiantoadflax5798 Год назад +2

    an animal model is gonna give him paws

  • @rapho8539
    @rapho8539 4 месяца назад +1

    Ritaline is like adderral, but without the smile.

    • @ToveriJuri
      @ToveriJuri 20 дней назад +2

      The quality-of-life improvements I've got from methylphenidate certainly makes me smile.

    • @allenwixted1992
      @allenwixted1992 10 дней назад +1

      @@ToveriJuri4 days in, life changing. Not sure what more you could want and I’m only on 1/4 the dose

  • @stoneneils
    @stoneneils 8 месяцев назад

    I think amphetamines are a problem for me...methy i was much happier and productive...amps i became a miserable sob addict. Problem is if they gave me the option today..I'm go with amps!! :)

  • @OConnorCarr-b7l
    @OConnorCarr-b7l 6 часов назад

    Wilson Nancy Martin Linda Walker Gary

  • @haaendaaz3619
    @haaendaaz3619 4 дня назад

    This looks biased. Where are the studies ?

    • @thecarlatreport
      @thecarlatreport  2 дня назад

      Here are the studies used to provide the information from this webinar!
      Arnold LE, J Atten Disord 2000;3(4)200-211
      Wolraich ML et al, Pediatrics 2019;144(4):e20192528
      Cortese S et al, Lancet Psychiatry 2018;5(9):727-738
      Moran LV et al, J Psychiatr Res 2015;71:41-47
      Curran C et al, Br J Psychiatry 2004;185:196-204
      Hegerl U et al, Eur Neuropsychopharmacol 2018;28(1):185-194.
      Farrell M et al, Lancet 2019;394(10209):1652-1667
      Korn L et al, Med Sci Monit 2019;25:3778-3787
      Li P et al, Hum Exp Toxicol 2021;40(9):1422-1433